UF News

FLIR Systems Acquires UF Startup Altavian, Inc.

FLIR Systems, Inc., a company specializing in the design and production of thermal imaging cameras, components and imaging sensors, announced that it has acquired UF startup Altavian, Inc., a privately-held manufacturer of small unmanned aerial systems (sUAS) for defense and public safety customers.

Barry Byrne, MD, Ph.D.: Landscape of Awareness for Neuromuscular Disease

Barry J. Byrne, MD, Ph.D., chief medical advisor of the Muscular Dystrophy Association and associate chair of pediatrics and director at the University of Florida Powell Center for Rare Disease Research and Therapy, talked with NeurologyLive about the virtual telethon to create awareness for a number of neuromuscular diseases.

AbFero to Receive € 2M Eurostars Funding for Parkinson’s Disease Therapy

AbFero Ltd., a subsidiary of UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical-stage pharmaceutical company dedicated to treating diseases of iron overload, announced the funding of approximately € 2M from EUREKA Eurostars for the development of iron-chelating compounds including their lead agent, SP-420, as a disease-modifying therapy for Parkinson's disease.

White Strawberry One of Two New UF/IFAS Varieties Ready for Harvest Season

Just in time for the west-central Florida strawberry harvesting season, which runs from now until the end of March, UF/IFAS is releasing not one, but two new varieties – and the white strawberry is one of them. The other: another cultivar that UF/IFAS’ primary breeder says tastes oh-so-good.

Sun BioPharma, Inc. Changes Name to Panbela Therapeutics Inc.

UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has announced the change of its corporate name to Panbela Therapeutics, Inc. effective December 2, 2020.

TearClear Announces Successful Completion of Pre-IND Meeting With the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma

UF startup and UF Innovate | Sid Martin Biotech resident client TearClear, an emerging ophthalmic pharmaceutical company, announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for the preservative free multi-dose delivery of a proprietary Latanoprost formulation, including the clinical study design for the registration study.

Want our news in your inbox every Monday morning? You can!

Subscribe Here